Collegium pharmaceutical, inc. (COLL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net income (loss)

450

-2,201

-6,109

-4,712

-9,700

9,086

-16,502

-13,060

-18,652

-17,403

-13,263

-21,121

-23,078

-27,559

-26,445

-24,519

-15,653

-9,525

-9,361

-4,675

-3,694

-3,469

-6,556

-4,119

-3,773

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization expense

10,295

3,688

3,688

3,688

3,688

15,494

32,407

32,407

29,526

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation expense

198

196

180

171

184

342

154

96

482

-

-

-

-

295

273

44

43

41

38

46

46

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

208

-

-

-

-

-

-

-

-

-

46

47

48

Lease incentive obligation

-

-

-

-

-

-

-

-

-

8

9

8

9

9

8

9

8

9

9

8

8

9

8

9

8

Stock-based compensation expense

4,951

3,966

4,137

4,162

4,263

3,598

3,926

3,526

2,728

2,078

2,100

1,946

1,821

1,650

1,641

1,395

1,101

992

503

601

113

6

5

6

5

Non-cash lease expense

18

-96

180

115

114

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense for Nucynta asset acquisition

1,336

-

-

-

-

2,169

5,641

5,943

5,528

-

-

-

-

-

-

-

-

-

-

-

-

1

2

3

1

Changes in operating assets and liabilities:
Accounts receivable

12,474

-11,427

3,101

-3,860

7,193

11,667

-1,847

2,344

56,067

4,146

946

1,528

1,220

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

6,714

883

-1,193

1,212

924

-1,412

685

642

-134

412

-119

25

179

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

2,990

277

-1,805

-433

-76

1,689

-2,131

85

523

1,024

-1,050

935

148

809

-237

716

-365

321

-354

-625

1,317

-322

157

2

-20

Refundable PDUFA fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-2,335

-

-

-

-

Accounts payable

-108

-5,734

1,040

-2,792

1,583

470

-7,013

9,356

3,652

702

-630

-1,181

-2,313

168

2,864

-114

2,651

336

930

60

-28

-573

551

1,068

-56

Accrued expenses

-15,968

13,284

-3,943

4,978

-8,263

7,814

-2,736

5,017

8,900

-10,842

9,241

3,595

-2,521

2,161

1,101

3,323

-15

-453

1,010

-1,067

872

-1,575

1,707

803

8

Accrued rebates, returns and discounts

14,337

-7,714

6,999

5,936

7,545

14,583

22,664

15,391

53,955

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease assets and liabilities

-

0

0

0

734

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

0

-10,361

1,666

3,751

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

0

0

0

-676

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-6,669

15,656

6,069

14,627

-8,569

42,288

41,834

55,605

29,663

-13,296

-12,567

-17,467

-23,688

-23,287

-19,414

-20,836

-11,516

-8,939

-6,536

-4,411

-1,681

-7,567

-4,408

-2,201

-3,771

Investing activities
Purchase of intangible asset

366,811

-

-

-

-

0

0

116

18,761

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

836

889

1,351

875

3,323

1,773

2,717

631

356

172

340

449

29

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-367,647

-889

-1,351

-875

-3,323

-1,773

-2,717

-747

-19,117

-172

-340

-449

-29

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Proceeds from issuances of common stock from employee stock purchase plans

357

0

373

0

444

0

607

0

510

0

468

0

673

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of lease note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15

15

16

13

16

15

17

14

Repayment of term note

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

251

166

202

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

16

-

-

-

-

Proceeds from the exercise of stock options

4,454

1,515

232

86

213

168

182

1,532

2,373

308

13

321

94

329

28

44

42

45

1

11

460

63

8

0

1

Payments made for employee restricted stock tax withholdings

1,358

101

198

35

488

90

114

140

216

0

17

0

51

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of term note, net of issuance costs of $2,200

192,373

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from convertible senior notes, net of issuance costs of $4,956

138,794

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for common stock offerings costs

-

-

-

-

-

-

0

0

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock from public offerings, net of issuance costs of $-, $30 and $1,198, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

85,721

445

0

51,174

-

-

-

-

-

-

-

-

Proceeds from term loan amendment, net of repayment of amended term loan

-

-

-

-

-

0

1

0

10,020

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of term loan

11,500

-

-

-

-

-

-

-

-

667

667

667

666

667

667

666

667

-

-

-

-

-

-

-

-

Proceeds from term loan amendment, net of repayment of amended term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,044

Repayment of asset acquisition obligations

-

-

-

-

-

33,750

33,750

51,455

13,045

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

323,120

1,414

407

51

169

-33,672

-33,074

-50,063

-388

24,554

9,309

-433

50

85,825

-194

-622

50,549

-637

-265

71,858

45,036

5,031

5,993

-17

1,031

Net decrease in cash, cash equivalents and restricted cash

-51,196

16,181

5,125

13,803

-11,723

6,843

6,043

4,795

10,158

11,086

-3,598

-18,349

-23,667

62,197

-19,719

-23,983

39,033

-

-6,953

67,424

43,355

-2,544

1,585

-2,218

-2,740

Supplemental disclosure of cash flow information
Cash paid for offering costs

-

-

-

-

-

0

0

0

30

-

-

-

-

-

0

128

384

-

105

1,433

165

-

-

-

-

Cash paid for interest

3,456

166

181

184

178

173

167

133

109

18

33

39

49

58

67

76

83

93

58

101

101

135

0

26

20

Supplemental disclosure of non-cash activities
Offering costs in accrued expenses

-

-

-

-

-

-

-

-

-

-

35

-87

112

-

-

-

128

-

-

-536

641

-

-

-

-

Acquisition of property and equipment in accounts payable and accrued expenses

392

-418

40

-298

810

1,805

272

1,055

129

119

-207

205

99

-

-

-

-

-

-

-

-

-

-

-

-

Asset acquisition transaction costs in accounts payable and accrued expenses

1,415

-

-

-

-

-

-

-

116

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued royalties discharged upon closing of asset acquisition

1,145

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory used in the construction and installation of property and equipment

394

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Term notes issuance costs in accounts payable and accrued expenses

256

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

-16

Convertible senior notes issuance costs in accounts payable and accrued expenses

517

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs in accrued expenses

-

-

-

-

-

-

-

0

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivable from stock option exercises in other current assets

-

-

0

-28

33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease assets assumed

-

0

0

0

9,957

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities assumed

-

0

0

0

10,691

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liabilities assumed from Nucynta asset acquisition included in accrued rebates, returns and discounts

-

-

-

-

-

0

0

-254

22,660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accruals of dividends and accretion to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

23,346

1,226

-

-

-

-

Conversion of bridge note to preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

-

-

-

-

Accruals of dividends and accretion to redemption value of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

814

Repayment of term note with proceeds of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

944